Skip to nav Skip to content

CDC/IDSA COVID-19 Clinician Call: COVID-19 Treatment Updates

Facebook Twitter LinkedIn Email

To Download a copy of the presentation click here.

To Download a copy of the Q&A Responses and important links click here.

*This call was funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number 6 NU50CK000477-04-01). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this call does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.

These one-hour webinars, held Saturdays at 3 p.m. ET, focus on timely issues of relevance to clinicians and feature case presentations by experts in the field, synthesis of new data, and an opportunity to engage with colleagues. Register for next week here.

Topic: COVID-19 Treatment Updates
During this call, experts from IDSA’s COVID-19 Treatment & Management Guideline Panel will discuss the latest data and recommendations on anti-SARS-CoV-2 monoclonal antibodies for treatment and prevention, ivermectin and the data underlying recommendations against its use, and recent findings on fluvoxamine as a therapy under investigation. Participants will have an opportunity to engage with the panel about these and other treatment topics during the Q&A/discussion.

Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA

Topics and Featured Experts:
Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment and Prevention
Rajesh Gandhi, MD, FIDSA
Director, HIV Clinical Services and Education
Massachusetts General Hospital
Co-Director, Harvard Center for AIDS Research
Professor of Medicine, Harvard Medical School
Chair, HIV Medicine Association

Kathryn M. Edwards, MD
Sarah H. Sell and Cornelius Vanderbilt Professor
Division of Infectious Diseases
Department of Pediatrics
Vanderbilt University Medical Center

Ivermectin: What are the Data and What’s Fueling its Use
Lindsey R. Baden, MD
Associate Professor of Medicine, Harvard Medical School
Director of Clinical Research, Division of Infectious Diseases
Brigham and Women's Hospital

Travis Stark, DPM
Physician Public Health, Centers for Disease Control and Prevention
Medical Officer, Adverse Event Monitoring Unit
Clinical Disease and Health Services (CDHS) Team
Health Systems and Worker Safety Task Force
CDC COVID-19 Response

Emerging Therapies under Investigation: Focus on Fluvoxamine
Shmuel Shoham, MD
Associate Professor of Medicine
Johns Hopkins Hospital

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.